Centre of Research Excellence - Personalising antimicrobial dosing to reduce resistance

Recommendations and guidelines

  1. Home
  2. Resources
  1. Denholm J, Venkatesh B, Bowen AC, Hammond NE, Jha V, McPhee G, McQuilten Z, O’Sullivan MVN, Paterson D, Price D, Rees M, Roberts JA, Jones M, Totterdell J, Snelling T, Trask N, Morpeth S, Tong SYC. ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. Trials 2022; in press
  2. Roberts JA, Sime F, Lipman J, Hernández-Mitre MP, Baptista JP, Brüggemann RJ, Darvall J, De Waele JJ, Dimopoulos G, Lefrant JY, Mat Nor MB, Rello J, Seoane L, Slavin MA, Valkonen M, Venditti M, Wong WT, Zeitlinger M, Roger C. A protocol for an international, multicentre pharmacokinetic study for Screening Antifungal Exposure in Intensive Care Units: The SAFE-ICU Study. Crit Care Resus 2022; in press (date accepted 21st October 2022; 20220117).
  3. Kong F, Unemo M, Lim SH, Latch N, Williamson DA, RobertsJA, Wallis SC, Parker SL, Landersdorfer CB, Yap T, Fairley CK, Chow EPF, Lewis DA, Hammoud M, Hocking JS. Optimisation of treatments for oral Neisseria gonorrhoeae infection: Pharmacokinetics Study (STI-PK project) – Study protocol for non-randomised clinical trial. BMJ Open 2022; in press (date accepted 18th October 2022; bmjopen-2022-064782.R1).
  4. Tong SYC, Mora J, Bowen AC, Cheng MP, Daneman N, Goodman AL, Heriot G, Lee TC, Lewis R, Lye DC, Marsh J, McGlothin A, McQuilten Z, Morpeth SC, Paterson DL, Price D, Roberts JA, Robinson JO, van Hal SJ, Wallis G, Webb S, Whiteway L, Yahav D, Davis JS. New Tools for an old foe: the Staphylococcus aureus Network Adaptive Platform Trial. Clin Infect Dis 2022; in press; doi: 10.1093/cid/ciac476.
  5. Irwin AD, Coin LJM, Harris PNA, Cotta MO, Bauer MJ, Buckley C, Balch R, Lipman J, Kruger P, Shekar K, Whiley D, Bialasiewisz, Beatson S, Paterson D, Clark J, Hajkowicz K, Raman S, Schlapbach LJ, Roberts JA.  Optimising treatment outcomes for children and adults through rapid genome sequencing of sepsis pathogens. A study protocol for a prospective, multi-centre trial (DIRECT). Front Cellular Infect Microbiol 2021; in press (date accepted 20th May 2021; 667680).
  6. Billot L, Lipman J, Brett SJ, De Waele JJ, Cotta MO, Davis JS, Finfer S, Hammond N, Knowles S, McGuinness S, Myburgh J, Paterson DL, Peake S, Rajbhandari D, Rhodes A, Roberts JA, Roger C, Shirwadkar C, Starr T, Taylor C, Dulhunty JM. Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis. Crit Care Resusc 2021; in press (20210028; date accepted 30th March 2021)
  7. Barreto EF, Rule AD, MD; Alshaer MH, Roberts JA, Abdul-Aziz MH, Scheetz M, Mara KC, Jannetto PJ, Gajic O, O'Horo JC, Boehmer KR. Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study. Implement Sci Comm 2021; in press (date accepted 9th March 2021; ISCM-D-21-00066).
  8. Koulenti D, Arvaniti K, Blot S, Brun-Buisson C, Deja M, DeWaele J, Du B, Dulhunty JM, Garcia-Diaz J, Judd M, Paterson DL, Putensen C, Reina R, Rello J, Restrepo M, Roberts JA, Sjovall F, Timsit JF, Tsiodras S, Jean-Ralph Zahar JR, Lipman J. ICU Nosocomial Pneumonia in the era of multidrug resistance - Protocol for an international, multi-centre, prospective, observational study of nosocomial pneumonia in intensive care units: The PneumoINSPIRE study. Crit Care Resus 2020; in press (date accepted 25th September 2020; 20200212).
  9. Denholm JT, Davis J, Paterson DL, Roberts JA, Morpeth S, Snelling T, Zentner D, Rees M, O’Sullivan M, Price D, Bowen A, Tong SYC. The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. Trials 2020; in press (date accepted 3rd July 2020; TRLS-D-20-00887).
  10. Hagel S, Fiedler S, Andreas H, Brinkmann A, Frey O, Hoyer H, Schlattmann P, Kiehntopf M, Roberts JA, Pletz MW, TARGET Study Group Trials. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multicenter, randomized controlled trial. Trials 2019; 20(1):330.
  11. Lipman J, Brett SJ, DeWaele JJ, Cotta MO, David JS, Finfer S, Glass P, Knowles S, McGuinness S, Myburgh J, Paterson DL, Peake SL, Rajbhandari D, Rhodes A, Roberts JA, Shirwadkar C, Starr T, Taylor C, Billot L, Dulhunty JM. A protocol for a Phase 3 multicentre randomised controlled trial of continuous versus intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis: the BLING III trial. Crit Care Resus 2019; 21(1):63-68.
  12. Paul SK, Roberts JA, Lipman J, Deans R, Samanta M. A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients with Renal Impairment. Clin Pharmacokinet 2019; 58(2):263-270.
  13. Dhanani J, Cohen J, Parker SL, Chan HK, Tang P, Ahern BJ, Khan A, Bhatt M, Goodman S, Diab S, Chaudhary J, Lipman J, Wallis SC, Barnett A, Chew M, Fraser JF, Roberts JA. A research pathway for the study of the delivery and disposition of nebulized antibiotics: an incremental approach from in vitro to large animal models. Intensive Care Med Exp 2018; 6(1):17.
  14. Roberts JA, Choi GYS, Joynt GM, Paul SK, Deans R, Peake S, Cole L, Stephens D, Bellomo R, Turnidge J, Wallis SC, Roberts MS, Roberts DM, Lassig-Smith M, Starr T, Lipman J. SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. BMC Infect Dis 2016; 16:103.
  15. Harris P, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials 2015; 16(1): 24.
  16. Ranganathan D, John GT, Healy H, Fassett RG, Lipman J, Kubler P, Ungerer J, McWhinney BC, Lim A, Purvey M, Reyaldeen R, Roberts MJ, Roberts JA. A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN)- an Open-label, Randomised Controlled Trial. BMJ Open 2013; 3(8).
  17. Shekar K, Roberts JA, Smith MT, Fung YL, Fraser JF. The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiol 2013;13(1):7
  18. Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Udy AA, Paul SK, Lipman J.A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. Crit Care Resus 2013; 15(3):179-85.
  19. Roberts JA, DeWaele JJ, Dimopoulos G, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J. DALI: Defining Antibiotic Levels in Intensive care unit patients: A multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infectious Diseases 2012; 12: 152.
  20. Shekar K, Fung YL, Diab S, Mullany DV, McDonald CI, Dunster KR , Fisquet S , Platts DG, Stewart D, Wallis SC, Smith MT , Roberts JA, Fraser JF. Development of simulated and ovine models of ECLS to improve understanding of circuit-host interactions. Crit Care Resus 2012; 14(2): 105-11.
  21. Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, Ghassabian S, Wallis SC, Levkovich B, Pellegrino V, McGuinness S, Parke R, Barnett AG, Walsham J, Mullany DV, Smith MT, Fraser JF. ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: A multi-centre study to optimize drug therapy during ECMO. BMC Anaesthesiol 2012; 12(1): 29.
  22. Al Balushi RM, Paratz JD, Cohen J, Banks M, Dulhunty J, Roberts JA, Lipman J. Effect of Intravenous Glutamine Supplementation in Trauma Patients Receiving Enteral Nutrition Study Protocol (GLINT Study): A Prospective, Blinded, Randomized, Placebo-controlled Clinical Trial. BMJ Open 2011; 1:e000334.
  23. Douglas A, Altukroni M, Udy AA, Roberts MS, Taraporewalla K, Jenkins J, Lipman J, Roberts JA. The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery. BMC Anesthesiol 2011, 11:5.
  24. Roberts JA, Roberts MS, Semark A, Udy, AA, Kirkpatrick CMJ, Paterson DL, Roberts MJ, Lipman J. Antibiotic dosing in the at risk critically ill patient: Linking pathophysiology with pharmacokinetics/ pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 2011, 11:3.
  25. Ranganathan D, Varghese JM, Fassett RG, Lipman J, D’Intini V, Healy H, Roberts JA. Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study. BMC Nephrology 2009, 10:42.